

# CD30+ Neoplasms of the Skin

Current Hematologic Malignancy Reports  
6, 245-250

DOI: 10.1007/s11899-011-0096-8

Citation Report

#	ARTICLE	IF	CITATIONS
1	Current Understanding of Cutaneous Lymphoma. <i>Dermatologic Clinics</i> , 2012, 30, 749-761.	1.0	2
2	The Role of Molecular Analysis in Cutaneous Lymphomas. <i>Seminars in Cutaneous Medicine and Surgery</i> , 2012, 31, 234-240.	1.6	10
3	Mimics of Cutaneous Lymphoma. <i>American Journal of Clinical Pathology</i> , 2013, 139, 536-551.	0.4	53
4	A Case of Lymphomatoid Papulosis Limited to Becker's Melanosis. <i>Dermatology</i> , 2013, 226, 124-127.	0.9	12
5	Targeting CD30 in Malignant Tissues: Challenges in Detection and Clinical Applications. <i>Pathobiology</i> , 2013, 80, 252-258.	1.9	13
6	CD30 expression in peripheral T-cell lymphomas. <i>Haematologica</i> , 2013, 98, e81-e82.	1.7	117
7	Angioinvasive Lymphomatoid Papulosis. <i>American Journal of Surgical Pathology</i> , 2013, 37, 1-13.	2.1	210
8	CD25+ folliculotropic S�azary syndrome with CD30+ large cell transformation. <i>Australasian Journal of Dermatology</i> , 2014, 55, e4-e8.	0.4	6
9	<i>Dermatopathology</i> . , 2014, , .		4
10	CD30 as a Therapeutic Target for Lymphoma. <i>BioDrugs</i> , 2014, 28, 181-209.	2.2	32
11	Primary cutaneous follicle center lymphoma with diffuse CD30 expression: A report of 4 cases of a rare variant. <i>Journal of the American Academy of Dermatology</i> , 2014, 71, 548-554.	0.6	23
12	Cutaneous CD30-Positive Lymphoproliferative Disorders. <i>Surgical Pathology Clinics</i> , 2014, 7, 203-228.	0.7	57
13	A Case of Refractory S�azary Syndrome With Large-Cell Transformation Responsive to Brentuximab Vedotin. <i>JAMA Dermatology</i> , 2014, 150, 210.	2.0	10
14	Choosing a systemic treatment for advanced stage cutaneous T-cell lymphoma: mycosis fungoides and S�azary syndrome. <i>Hematology American Society of Hematology Education Program</i> , 2015, 2015, 529-544.	0.9	14
15	Contribution of longitudinal follow up and clinical pathological correlation in the diagnosis of CD30-positive skin infiltrates. <i>Journal of Cutaneous Pathology</i> , 2015, 42, 452-458.	0.7	2
16	New variant lymphomatoid papulosis type E preceding and coexisting with mycosis fungoides – a case report and review of the literature. <i>Journal of Cutaneous Pathology</i> , 2015, 42, 1018-1023.	0.7	13
18	<i>Atlas of Cutaneous Lymphomas</i> . , 2015, , .		4
19	Shared clonality in distinctive lesions of lymphomatoid papulosis and mycosis fungoides occurring in the same patients suggests a common origin. <i>Human Pathology</i> , 2015, 46, 558-569.	1.1	43

#	ARTICLE	IF	CITATIONS
20	CD30 As a Target for the Treatment of Cutaneous T-Cell Lymphoma. Journal of Clinical Oncology, 2015, 33, 3691-3696.	0.8	8
21	Rapid response of nodular <scp>CD</scp>30- positive mycosis fungoides to brentuximab vedotin. British Journal of Haematology, 2015, 168, 617-617.	1.2	9
22	Results of a Phase II Trial of Brentuximab Vedotin for CD30<sup>+</sup> Cutaneous T-Cell Lymphoma and Lymphomatoid Papulosis. Journal of Clinical Oncology, 2015, 33, 3759-3765.	0.8	255
23	Molecular Oncologic Testing of Skin and Adnexa Tumors. , 2015, , 567-618.		0
24	Peripheral T- cell and <scp>NK</scp> cell lymphoproliferative disorders: cell of origin, clinical and pathological implications. Immunological Reviews, 2015, 263, 124-159.	2.8	30
25	Multiple cutaneous lymphoproliferative disorders showing a retained tumor clone by <scp>T</scp>- cell receptor gene rearrangement analysis: a case series of four patients and review of the literature. International Journal of Dermatology, 2016, 55, e62-71.	0.5	14
26	Lymphomatoid Papulosis in Children and Adolescents: A Systematic Review. American Journal of Clinical Dermatology, 2016, 17, 319-327.	3.3	44
27	Primary cutaneous CD30<sup>+</sup> lymphoproliferative disorders. JDDG - Journal of the German Society of Dermatology, 2016, 14, 767-782.	0.4	12
28	Cutaneous lymphoma: Kids are not just little people. Clinics in Dermatology, 2016, 34, 749-759.	0.8	23
29	Prim-Är kutane CD30<sup>+</sup> lymphoproliferative Erkrankungen. JDDG - Journal of the German Society of Dermatology, 2016, 14, 767-784.	0.4	8
30	New uses for brentuximab vedotin and novel antibody drug conjugates in lymphoma. Expert Review of Hematology, 2016, 9, 767-780.	1.0	11
31	Lymphomatoid papulosis: Treatment response and associated lymphomas in a study of 180 patients. Journal of the American Academy of Dermatology, 2016, 74, 59-67.	0.6	96
32	Retrospective Analysis of Prognostic Factors in 187 Cases of Transformed Mycosis Fungoides. Clinical Lymphoma, Myeloma and Leukemia, 2016, 16, 49-56.	0.2	44
33	A Single-Center Experience With Brentuximab Vedotin in Gamma Delta T-Cell Lymphoma. Clinical Lymphoma, Myeloma and Leukemia, 2016, 16, e15-e19.	0.2	16
34	Lymphomatoid papulosis: A cutaneous lymphoproliferative disorder in a patient on fingolimod for multiple sclerosis. Multiple Sclerosis Journal, 2016, 22, 122-124.	1.4	32
35	Prognostic significance of CD30 expression in nasal natural killer/T-cell lymphoma. Oncology Letters, 2017, 13, 1211-1215.	0.8	12
36	A new era for cutaneous CD30-positive T-cell lymphoproliferative disorders. Seminars in Diagnostic Pathology, 2017, 34, 22-35.	1.0	47
37	Diagnostic, prognostic and therapeutic role of CD30 in lymphoma. Expert Review of Hematology, 2017, 10, 29-37.	1.0	43

#	ARTICLE	IF	CITATIONS
38	Brentuximab Vedotin for Patients With Refractory Lymphomatoid Papulosis. <i>JAMA Dermatology</i> , 2017, 153, 1302.	2.0	28
39	Mycosis fungoides mit groÙzelliger, CD30-positiver Transformation unter dem klinischen Bild einer vernarbenden Alopezie. <i>JDDG - Journal of the German Society of Dermatology</i> , 2017, 15, 1021-1023.	0.4	0
40	Mycosis fungoides with CD30-positive large-cell transformation clinically mimicking scarring alopecia. <i>JDDG - Journal of the German Society of Dermatology</i> , 2017, 15, 1021-1023.	0.4	0
41	Brentuximab vedotin in CD30 <sup>+</sup> cutaneous lymphoma: How do we treat, how shall we treat? A review of the literature. <i>British Journal of Dermatology</i> , 2017, 177, 1503-1509.	1.4	27
42	Cutaneous T-cell lymphomas: Focusing on novel agents in relapsed and refractory disease. <i>Cancer Treatment Reviews</i> , 2017, 61, 61-69.	3.4	27
43	Not bitten by the bug: A CD30 <sup>+</sup> lymphoproliferative disorder masquerading as arthropod bites. <i>American Journal of Hematology</i> , 2018, 93, 315-316.	2.0	1
44	A Systematic Approach to the Cutaneous Lymphoid Infiltrates: A Clinical, Morphologic, and Immunophenotypic Evaluation. <i>Archives of Pathology and Laboratory Medicine</i> , 2019, 143, 958-979.	1.2	6
45	Antibody-Directed Therapies: Toward a Durable and Tolerable Treatment Platform for CTCL. <i>Frontiers in Oncology</i> , 2019, 9, 645.	1.3	8
46	Lymphomatoid papulosis type E with a CD56+ immunophenotype presenting with purpura-like lesions. <i>Journal of Cutaneous Pathology</i> , 2019, 46, 542-545.	0.7	8
47	Common origin of sequential cutaneous CD30+ lymphoproliferations with nodal involvement evidenced by genome-wide clonal evolution. <i>Histopathology</i> , 2019, 74, 654-662.	1.6	6
48	Brentuximab Vedotin in the Treatment of Peripheral T Cell Lymphoma and Cutaneous T Cell Lymphoma. <i>Current Hematologic Malignancy Reports</i> , 2020, 15, 9-19.	1.2	25
49	Critical concepts and management recommendations for cutaneous T-cell lymphoma: A consensus-based position paper from the Italian Group of Cutaneous Lymphoma. <i>Hematological Oncology</i> , 2021, 39, 275-283.	0.8	4
50	Combination of brentuximab vedotin with skin-directed therapies extends the time to the next therapeutic line in patients with cutaneous T-cell lymphoma. <i>JDDG - Journal of the German Society of Dermatology</i> , 2021, 19, 383-387.	0.4	6
52	Novel therapies targeting cutaneous T cell lymphomas and their microenvironment. <i>Seminars in Hematology</i> , 2021, 58, 103-113.	1.8	4
54	The expression of CD30 and its clinico-pathologic significance in peripheral T-cell lymphomas. <i>Expert Review of Hematology</i> , 2021, 14, 777-787.	1.0	17
55	Remission of refractory granulomatous primary cutaneous anaplastic large cell lymphoma to brentuximab vedotin. <i>BMJ Case Reports</i> , 2021, 14, e242896.	0.2	0
56	Primary Cutaneous Lymphomas. , 2014, , 173-191.		0
57	Cutaneous Lymphomas and Hematopathology. , 2014, , 469-501.		0

#	ARTICLE	IF	CITATIONS
58	Lymphomatoid Papulosis. , 2015, , 109-118.		0
60	Lymphomatoid papulosis mimicking cutaneous histiocytosis. Gazzetta Medica Italiana Archivio Per Le Scienze Mediche, 2019, 178, .	0.0	0
61	Clinical and Immunomorphological Characteristics of Lymphomatoid Papulosis Type E (Literature) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	0.1	1